Most Popular
Advertising
Videos & Images
Fun Stuff
Content Section
Booking Portal
News Headlines
111 times read : Adjust font size: 
 |
Yesterday, ZymoGenetics Inc ( ZGEN ) announced that its rheumatoid arthritis drug Atacicept, failed to reach its goal of controlling the disease in mid-stage studies. The data did not support a direct move to late-stage trials. However, the study confirmed the biological effect of Atacicept, and did not display any unexpected side effects. Atacicept is being developed in collaboration with Merck Serono S.A. (formerly Serono S.A.), an affiliate of Merck KGaA, Darmstadt, Germany. Under this a
Read this article...
Comments (0 posted)
